RT Journal Article
SR Electronic
T1 Clinical Efficacy of Tumor Treating Fields for Newly Diagnosed Glioblastoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5801
OP 5806
DO 10.21873/anticanres.14597
VO 40
IS 10
A1 YANG LIU
A1 MYLA S. STRAWDERMAN
A1 KWANZA T. WARREN
A1 MARGIE RICHARDSON
A1 JENNIFER N. SERVENTI
A1 NIMISH A. MOHILE
A1 MICHAEL T. MILANO
A1 KEVIN A. WALTER
YR 2020
UL http://ar.iiarjournals.org/content/40/10/5801.abstract
AB Background/Aim: Whether adding tumor treating fields (TTF) to the Stupp protocol increases survival for glioblastoma (GBM) patients in routine clinical care remains unknown. Patients and Methods: We retrospectively identified adult patients with newly diagnosed GBM (n=104) treated with the Stupp protocol or TTF at our Institution. Results: Thirty-six percent (37/104) of patients received TTF in conjunction with the Stupp protocol and these patients had increased 6-month (p=0.006) and 1-year (p=0.170), but not 2-year survival rates compared to the 67-patients who received Stupp alone. The improvement of survival rate at 6-month was further confirmed by a modified Poisson model (p=0.010). However, we did not observe any improvement in overall survival (OS) with a Cox model. Conclusion: While adding TTF to the Stupp protocol appeared to benefit patients with newly diagnosed GBM, this effect was mild and may be largely due to selection bias.